Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: Case report of a pancreatico-renal transplant recipient

被引:10
作者
Benz, C
Holz, G
Michel, D
Awerkiew, S
Dries, V
Stippel, D
Goeser, T
Busch, DH
机构
[1] Department of Gastroenterology, University of Cologne, Cologne
[2] Institute of Virology, University of Ulm, Ulm
[3] Department of Virology, University of Cologne, Cologne
[4] Department of Pathology, University of Cologne, Cologne
[5] Department of Surgery, University of Cologne, Cologne
[6] Inst. Med. Microbiol., Immunol./Hyg., Technical University Munich, Munich
[7] Department of Gastroenterology, University Hospital of Cologne, 50931 Cologne
关键词
D O I
10.1097/01.TP.0000052664.18029.E6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Pancreas-kidney transplant recipients are at high risk for cytomegalovirus (CMV) disease despite prophylactic ganciclovir therapy. Because the impact of antiviral therapy on anti-CMV immune reactions is unknown, CMV-specific T-cell subsets in primary and recurrent CMV infection were analyzed in a pancreas-kidney transplant case study. Methods. Major histocompatibility complex class I tetramers were used to detect peripheral CMV pp65-specific CD8(+) T cells. Intracellular cytokine staining was used to determine the frequency of CMV-specific CD4(+) T cells. Conventional virologic parameters and routine laboratory parameters were monitored. For ganciclovir resistance testing, CMV-UL97 genotyping was performed. Results. Despite prophylactic ganciclovir therapy, primary CMV infection induced in vivo expansion of activated CMV-specific CD8(+) T cells. Interestingly, viral dissemination during recurrent CMV disease was a result of partially ganciclovir-resistant CMV. Recovery after discontinued ganciclovir treatment was associated with the expansion of CMV-specific CD4(+) T cells. Conclusion. Immunologic monitoring may contribute to clinical management of recurrent CMV disease.
引用
收藏
页码:724 / 727
页数:4
相关论文
共 10 条
[1]   Activated virus-specific T cells are early indicators of anti-CMV immune reactions in liver transplant patients [J].
Benz, C ;
Utermöhlen, O ;
Wulf, A ;
Villmow, B ;
Dries, V ;
Goeser, T ;
Koszinowski, U ;
Busch, DH .
GASTROENTEROLOGY, 2002, 122 (05) :1201-1215
[2]   Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation [J].
Emery, VC .
REVIEWS IN MEDICAL VIROLOGY, 2001, 11 (02) :83-86
[3]   Long-term results of pancreas transplantation under tacrolimus immunosuppression [J].
Jordan, ML ;
Shapiro, R ;
Gritsch, HA ;
Egidi, F ;
Khanna, A ;
Vivas, CA ;
Scantlebury, VP ;
Fung, JJ ;
Starzl, TE ;
Corry, RJ .
TRANSPLANTATION, 1999, 67 (02) :266-272
[4]   Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation [J].
Kaufman, DB ;
Leventhal, JR ;
Gallon, LG ;
Parker, MA ;
Koffron, AJ ;
Fryer, JP ;
Abecassis, MM ;
Stuart, FP .
TRANSPLANTATION, 2001, 72 (12) :1940-1945
[5]  
Keay S, 1999, Transpl Infect Dis, V1 Suppl 1, P19
[6]   Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants [J].
Limaye, AP ;
Corey, L ;
Koelle, DM ;
Davis, CL ;
Boeckh, M .
LANCET, 2000, 356 (9230) :645-649
[7]  
Lo A, 2001, Transpl Infect Dis, V3, P8, DOI 10.1034/j.1399-3062.2001.003001008.x
[8]  
Michel D, 2001, J MED VIROL, V65, P70
[9]   Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation [J].
Rosen, HR ;
Benner, KG ;
Flora, KD ;
Rabkin, JM ;
Orloff, SL ;
Olyaei, A ;
Chou, SW .
TRANSPLANTATION, 1997, 63 (03) :476-478
[10]  
SAWYER MD, 1993, ARCH SURG-CHICAGO, V128, P165